Mammalian cell banking market seen reaching $5.31B by 2030

The Business Research Company says the mammalian cell banking market will grow from $3.14 billion in 2025 to $3.5 billion in 2026, then climb to $5.31 billion by 2030. The report points to cell-based therapies, biopharmaceutical growth and tighter quality standards as the main forces behind the expansion.

Why it matters: - Mammalian cell banking is becoming a core part of biopharmaceutical and regenerative medicine supply chains. - The market’s growth reflects rising demand for standardized, traceable cell lines used in research, biologics and advanced therapies. - Expansion in this market can affect manufacturing reliability, regulatory compliance and the pace of cell-based treatment development.

What happened: - The Business Research Company released its mammalian cell banking market report for 2026, covering market size, trends and global forecasts through 2035. - The report estimates the market will rise from $3.14 billion in 2025 to $3.5 billion in 2026. - The report forecasts the market will reach $5.31 billion by 2030. - North America held the largest share of the global mammalian cell banking market in 2025. - The report also examines Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Download a free sample of the report. - View the full report.

The details: - Mammalian cell banking means the controlled creation, preservation and storage of characterized mammalian cell stocks at very low temperatures. - The process is designed to keep cells viable, genetically stable and functionally consistent over time. - The report says past growth was driven by monoclonal antibodies, vaccine production, stricter quality rules, academic research expansion and biologics commercialization. - Future growth is expected to come from gene therapy, personalized medicine, biosimilar products, cell-based therapy pipelines and long-term traceability needs. - Emerging trends include standardized cell line preservation, biopharmaceutical pipeline growth, CGMP-compliant cell banks, greater attention to genetic stability and more outsourcing to specialized facilities. - Cell-based therapies are a major demand driver because they use living cells to repair, replace or regenerate damaged tissues and organs. - The report ties that demand to rising chronic and rare disease burdens that are pushing interest in more precise treatments. - Mammalian cell banks supply high-quality cells that help support consistency, safety and scalability in regenerative treatment development and manufacturing. - In April 2024, the American Society of Gene and Cell Therapy reported more therapies entering clinical pipelines, with Phase I trials up 11% since late 2022. - The report says regulatory demands, biopharmaceutical research growth, biologics commercialization, genetic stability concerns and CGMP standards also support the market. - Outsourcing cell banking to specialized providers is becoming more common as companies try to focus on core research and development.

Between the lines: - The market outlook suggests cell banking is shifting from a back-office lab function to a strategic enabler for advanced therapy production. - Strong demand for compliance and traceability points to a market where quality control matters as much as scale. - North America’s lead suggests the region remains the most mature market for biopharma infrastructure and cell-therapy development.

What's next: - The Business Research Company expects the market’s growth rate to ease slightly after 2026, but still remain above 11% annually through 2030. - Ongoing development in gene therapy and cell-based pipelines is likely to keep demand elevated for preserved, standardized cell lines. - More companies may shift banking work to specialized vendors as the need for CGMP-compliant operations expands.

The bottom line: - Mammalian cell banking is set for steady double-digit growth as cell therapies, biologics and regulatory pressure raise the value of reliable, well-documented cell lines.